Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

AbbVie records a $3.5 billion impairment charge following the failure of emraclidine in Phase II schizophrenia trials.

Drugmaker AbbVie warned it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate, a ...

Michele Buck, a 20-year veteran of Hershey who assumed leadership in 2017, said she would step down from her roles as president and chief executive on June 30, 2026. The merger combines two of the ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

(Reuters) - AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development ...

When it comes to dividend investing, there are two basic paths you can take. If you can't decide which dividend investing ...